**Figure S1** No significant association between IL-18 or CXCL10 level and PFS was observed in the chemotherapy trial arms. The 2-sided log-rank test P values for the survival analysis, the PFS HR (based on Cox proportional hazard model) between CXCL-10 and IL-18 subgroups are indicated in patients with NSCLC treated with chemotherapy (n=23). (A) Probability of PFS with ≥60.95 versus <60.95 pg/mL CXCL10 levels. (B) Probability of PFS with ≥70.44 versus <70.44 pg/mL IL-18 levels. HR, hazard ratio.